Protocol # 038-00: A Phase II Randomized, Dose Ranging, Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Doses of MK-5172 when Administered Concomitantly with Peginterferon alfa-2b and Rabavirin in Treatment Naive Subjects wi

Project: Research project

Project Details

Effective start/end date1/24/131/24/16


  • Merck Sharp & Dohme Corporation (Protocol # 038-00)